{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Anthem Biosciences Ltd
Anthem Biosciences Declines 3.20% Amid Mixed Technical Signals and Market Volatility
Anthem Biosciences Ltd closed the week ending 13 March 2026 at Rs.639.90, down 3.20% from the previous Friday’s close of Rs.661.05. Despite the stock’s decline, it outperformed the Sensex, which fell 4.87% over the same period. The week was marked by significant volatility, technical momentum shifts, a downgrade to a Sell rating, and disappointing quarterly financial results, all contributing to the stock’s cautious outlook.
Anthem Biosciences Ltd Technical Momentum Shifts Amid Mixed Market Signals
Anthem Biosciences Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a modest day gain of 1.82%, the stock’s technical indicators present a complex picture, reflecting mixed signals across weekly and monthly timeframes. This analysis delves into the recent price action, key technical indicators such as MACD, RSI, moving averages, and broader market comparisons to provide investors with a comprehensive view of the stock’s current positioning.
Anthem Biosciences Downgraded to Sell Amid Technical and Financial Weakness
Anthem Biosciences Ltd has seen its investment rating downgraded from Hold to Sell as of 9 March 2026, reflecting a combination of deteriorating technical indicators, disappointing quarterly financial results, and valuation concerns. The company’s Mojo Score has declined to 40.0, signalling caution for investors amid sideways technical trends and weakening profitability metrics.
Anthem Biosciences Ltd Hits Intraday Low Amid Price Pressure on 9 Mar 2026
Anthem Biosciences Ltd experienced a notable decline today, touching an intraday low of Rs 608.4, reflecting sustained price pressure amid broader market weakness and sector underperformance.
Anthem Biosciences Ltd Technical Momentum Shifts Amid Market Volatility
Anthem Biosciences Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish stance to a sideways trend. Despite a recent downgrade in its Mojo Grade from Sell to Hold, the stock’s technical indicators reveal a complex picture of mixed signals, reflecting cautious investor sentiment amid volatile price action.
Anthem Biosciences Declines 5.66% Amid Mixed Technical Signals and Sector Challenges
Anthem Biosciences Ltd experienced a challenging week, with its share price declining 5.66% from ₹700.70 to ₹661.05, underperforming the Sensex which fell 3.00%. The stock’s technical momentum shifted from sideways to mildly bullish midweek, coinciding with a MarketsMOJO upgrade from Sell to Hold. Despite this, mixed financial results and elevated valuation metrics tempered optimism, leaving investors with a nuanced outlook amid sector headwinds.
Anthem Biosciences Ltd Upgraded to Hold on Technical and Financial Reassessment
Anthem Biosciences Ltd has seen its investment rating upgraded from Sell to Hold as of 4 March 2026, reflecting a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality. Despite recent quarterly setbacks, the company’s robust management efficiency and long-term growth prospects have contributed to this reassessment, signalling cautious optimism among investors.
Anthem Biosciences Ltd Technical Momentum Shifts to Mildly Bullish Amid Mixed Returns
Anthem Biosciences Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance on the weekly charts. Despite a recent day decline of 3.58%, the stock’s technical indicators suggest a nuanced outlook, with mixed signals from MACD, RSI, and moving averages pointing to cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.
Anthem Biosciences Ltd Faces Technical Momentum Shift Amid Mixed Market Signals
Anthem Biosciences Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces and indicator signals. Despite a recent downgrade in its Mojo Grade to Sell from Hold, the stock’s price action and technical indicators reveal a nuanced picture that investors should carefully analyse.
Anthem Biosciences Ltd is Rated Sell
Anthem Biosciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 March 2026, providing investors with the latest insights into the company’s performance and outlook.
When is the next results date for Anthem Biosciences Ltd?
The next results date for Anthem Biosciences Ltd is February 5, 2026.
How has been the historical performance of Anthem Bioscienc?
Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.
Is Anthem Bioscienc overvalued or undervalued?
As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.
Is Anthem Bioscienc overvalued or undervalued?
As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and significantly higher valuation metrics compared to peers, indicating it is overvalued despite past strong returns.
Is Anthem Bioscienc overvalued or undervalued?
As of August 29, 2025, Anthem Bioscienc is considered very expensive and overvalued, with a PE Ratio of 90.82, an EV to EBITDA of 65.82, and a Price to Book Value of 18.59, all significantly higher than industry norms and its peers.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
